Emergency Treatment of Multiply Injured Patients with Unstable Disruption of the Posterior Pelvic Ring by Using the “C–Clamp”

Abstract Purpose: Evaluation of the therapeutic usefulness of the “pelvic C–clamp” (PCC) during emergency treatment of multiply injured patients with unstable disruption of the posterior pelvic ring. Patients and Methods: The data of 28 patients with polytrauma in combination with an unstable fracture of the posterior pelvic ring (average Injury Severity Score [ISS]: 49 points; average Polytrauma Score [PTS]: 41 points) were retrospectively analyzed from the moment they were admitted to the emergency room until 48 h after admittance. The PCC was used immediately for primary stabilization of the pelvis after clinical diagnosis of the unstable pelvic fracture. Main outcome measurements: development of mean blood pressure, development of oxygenation level, period of time until the PCC was placed, number of blood units needed, period of time until circulatory stabilization occurred. Results: The PCC was applied in all cases within an average of 64.7 min after trauma. Seven patients (25%) died within the first 45 min after admission. The surviving patients showed:• an increase in mean blood pressure of 25% 20 min after application of the PCC,• a hemodynamic stabilization 6 h after application of the PCC,• a stabilization of the oxygenation level 6 h after application of the PCC,• a decrease in the number of required blood units 6 h after application of the PCC. Conclusion: The present study shows, that the application of the PCC to critically injured patients with unstable pelvic fractures leads to stabilization of the vital parameters within a short period of time.     

膝前框形钢丝内固定治疗髌骨骨折

目的　总结采用钢丝环扎 +膝前方框形张力带钢丝内固定法治疗髌骨骨折的经验和临床效果。方法　对 3 5例髌骨骨折应用此方法治疗 ,其中男性 2 4例 ,女性 11例 ,3 0例获得 3～ 2 4个月随访。结果　优 19例 ,良 10例 ,可1例 ,优良率 96 7%。术后未出现骨折再移位 ,无伤口感染。愈合时间 6～ 12周。结论　该方法符合生物力学原理 ,操作简便 ,适应证广 ,能早期关节活动 ,是治疗髌骨骨折的理想方法之一。     

经后路钛网椎板成形侧块内固定术治疗脊髓型颈椎病的疗效观察

目的 观察后路钛网椎板成形侧块内固定加植骨术治疗脊髓型颈椎病的临床效果。方法 自1999年至今，共有16例脊髓型颈椎病患者经后路钛网椎板成形侧块内固定加植骨术治疗，对治疗结果进行临床及X线评定。结果 通过平均2年5个月的随访，所有病例都得到了改善，其中优6例、良8例、可2例，优良率为93．8％；术后椎管矢状径平均增加4．2mm，钛网无位置变化，并已被再生骨固定。结论 在进行后路减压的同时，钛网椎板成形及侧块内固定，尤其适用于有节段性不稳的脊髓型颈椎病并椎管狭窄、后纵韧带骨化症的治疗。     

Prospective randomised study of urgent haemorrhoidectomy compared with non-operative treatment in the management of prolapsed thrombosed internal haemorrhoids

OBJECTIVE: To compare the outcome of urgent haemorrhoidectomy with conservative treatment for prolapsed thrombosed internal haemorrhoids. METHODS: A prospective randomised study of 50 patients with prolapsed thrombosed internal haemorrhoids was carried out using clinical and ultrasonic outcome measures. Peri-operative bed occupancy and the presence of symptoms at 6 and 24 months were compared. Endoanal ultrasonic scanning was carried out to investigate anal sphincter integrity in those patients willing to be studied. RESULTS: The median length of hospital stay for the group treated conservatively; 2 nights (range 1-9 nights) was significantly shorter than for the group treated by urgent haemorrhoidectomy; 4 nights (range 1-12 nights, P < 0.01). There was no difference between treatment groups in the number of patients with symptoms at six or 24 months. Urgent haemorrhoidectomy was associated with a significantly higher incidence of endosonographically detected anal sphincter damage in 18 patients: 66%vs 0% (P = 0.009). CONCLUSION: Conservative treatment for prolapsed thrombosed internal haemorrhoids is associated with shorter in patient stay and less anal sphincter damage compared with operative treatment.     

股骨转子间骨折GAMMA钉治疗临床分析

目的：评价GAMMA钉治疗股骨转子间骨折的效果。方法：对32例股骨转子间骨折采用GAMMA钉治疗。结果：经6～18月随访，所有病例均获骨性愈合，下肢功能及关节活动良好。其中1例为粉碎性骨折内固定后出现髋内翻，按X线评分标准90％病人满意。结论：GAMMA钉治疗股骨转子间骨折效果满意。     

Treatment of osteoporosis in men

Osteoporosis in men is recognised worldwide as an important and increasing public health problem. The causes are more heterogeneous than those in women. About 50% are diagnosed as secondary cases. In some secondary forms of osteoporosis the specific diagnosis results in additional therapeutic options (e.g. androgen therapy in proven hypogonadism). The basic therapy for osteoporosis in men is no different to that in postmenopausal women, namely recommendations for counteracting modifiable risk factors, especially with regard to diet, physical exercise, and calcium and vitamin D supplementation. Concerning specific drug medications, however, even today there is still a therapeutic dilemma in male osteoporosis. While older substances (e.g. calcitonin, fluoride, alfacalcidol) are approved for both sexes, all newer medications have primarily been approved for the treatment of postmenopausal osteoporosis. Health authorities request studies in purely male populations. For new drugs, fracture data are necessary while for new substances within a class (e.g. bisphosphonates), at the very least consistent effects on bone mineral density (BMD) and bone turnover markers are requested. Due to these regulatory rules, ibandronate, teriparatide and strontium ranelate are not approved in the European Union. Some years ago, alendronate was the first bisphosphonate that was approved for the treatment of men with osteoporosis, based on consistent results from two independent male studies using a daily 10 mg dosage. Very recently risedronate was approved by the FDA and EMEA. A randomised, placebo-controlled multicentre trial of 285 male patients showed, after 2 years, a 5.8% increase in lumbar spine BMD in the risedronate 35 mg once weekly group vs 1.2% in the placebo group. In a prospective controlled study on 316 men with primary or secondary osteoporosis we found, after 12 months, a lumbar spine BMD of +4.7% vs +1.0% in controls. The number of patients with one or more new vertebral fractures was 8 in the risedronate group and 20 in the placebo group (a fracture reduction of 60%). Furthermore, we found a significantly smaller decrease in height and a steeper decrease in back pain in the risedronate group. Risedronate is the first oral bisphosphonate available for men with the more comfortable once weekly dosage.     

经皮椎体成形术中骨水泥对老年骨质疏松症患者凝血功能的影响

目的 观察经皮椎体成形术(PVP)中骨水泥对老年骨质疏松症患者凝血功能的影响.方法 于椎弓根穿刺前10 min、注入骨水泥后1、20 min、2 h分别抽血检测11例患者的凝血功能相关指标,包括血浆凝血酶原时间(PT)、活化的部分凝血酶原时间(APTT)、血浆纤维蛋白原(FIB)和鱼精蛋白副凝固实验(3P实验),并汇总数据进行统计学分析.结果 PVP中骨水泥注入后20 min,PT缩短、FIB增高、3P实验阳性率升高(P<0.05),骨水泥注入2 h后基本恢复至注入前水平.除1例患者PTA术后2 h稍高于正常值(126%),其余患者各个时间点的各项指标均在正常参考值范围内.结论 PVP术中注入骨水泥对于凝血功能正常的患者基本安全,但在注入后会产生一过性轻微的高凝倾向.     

游离腓骨皮瓣结合交锁髓内钉治疗前臂复合组织缺损

目的 探讨应用游离腓骨皮瓣结合交锁髓内钉治疗前臂复合组织缺损的可行性与疗效.方法 对5例前臂骨(尺骨和/或桡骨)和软组织缺损的患者,应用同侧/对侧游离腓骨皮瓣移植,同时应用Smith-Nephew交锁髓内钉对游离腓骨进行固定.供区植皮.结果 5例皮瓣全部存活.根据Anderson评分标准评定:优1例,良3例,可1例.骨折愈合时间为12～17周,平均14.6周,术后无骨不连与感染发生.结论 游离腓骨皮瓣结合交锁髓内钉是治疗前臂复合组织缺损的可行方法.     

凹槽交锁髓内钉治疗股骨多段骨折(附18例报告)

目的探讨一种新型交锁髓内钉-凹槽交锁股骨髓内钉(Biorigid nail femur，简称BNF)治疗股骨多段骨折的方法。方法自2002年3月～2003年10月应用德国aap公司生产的BNF治疗骨折多段骨折18例。结果本组经过3～18个月、平均9个月的随访。骨折均愈合，膝、髋关节恢复良好。结论BNF具有设计独特、内固定可靠、主钉全程均可交锁的特点，能满足自股骨转子下到股骨髁之间一处或多处骨折内固定需要。     

手法治疗肘关节错缝86例

2000年1月-2005年10月共治疗肘关节错缝86例,临床效果满意,现报告如下。1临床资料86例中男61例,女25例;年龄13~46岁。受伤机制:均为跌倒时手掌着地,肘关节过伸导致。摄X线片未见骨折及关节异常。肘关节伸屈活动障碍,伸20°~40°,屈90°~110°,屈伸平均(70·57°±3·01°)的活动范围。肘关节轻度肿胀,以内后方为甚,压痛点为尺骨半月切迹的内侧,强作旋后活动时会引起剧烈疼痛,肘三角正常。受伤至就诊时间1~3 d,平均1·5 d。2治疗方法2·1复位左肘错缝者坐于靠背椅上,助手立于患者侧背后方,紧握患者上臂,术者于患者前侧,左手握患者腕部,右手…